BioStone > Veterinary Biologics and Vaccine Solutions > Autogenous Bacterin Manufacturing Services
Autogenous Bacterin Manufacturing Services
U.S.-based contract manufacturing of herd-specific autogenous bacterins under veterinary oversight.
Autogenous Bacterin Programs We Support
Cattle
Equine
Swine
Caprine/Ovine
Poultry
Why Partner with BioStone?
A BioStone Animal Health brand
Built on AAH’s legacy and BioStone’s resources, we deliver dependable autogenous bacterins with consistent quality and predictable timelines.
- Four Decades of Proven Autogenous Expertise Built on AAH’s established formulation methods and production experience.
- Advanced Adjuvant Systems Carefully selected adjuvant platforms to optimize immune response and clinical performance.
- Multi-Antigen Custom Combinations (Up to 5 Isolates) Formulations tailored to your diagnostic findings and herd-specific pathogen profile.
- Refined Processing Protocols Improved manufacturing workflows that enhance efficacy, consistency and quality.
- High Manufacturing Standards Strict quality control measures to ensure purity, safety, and consistent product performance.
- Competitive Pricing Practical solutions aligned with your economic considerations.
- Reliable, On-Time Delivery Predictable production timelines to keep vaccination programs on schedule.
What are Autogenous Bacterins?
Autogenous bacterins are custom veterinary vaccines made from bacterial isolates collected from animals within a specific herd or flock. BioStone currently focuses on autogenous bacterins to support veterinarians when commercial vaccines are unavailable, insufficient, or not well matched to circulating strains. We support programs across bovine, swine, poultry, equine, and small ruminant species.
Do you have questions?
Our Autogenous Bacterin Manufacturing Services
Veterinarian-collected samples are submitted to a diagnostic lab for bacterial isolation/identification; confirmed isolate(s) are then forwarded (at the veterinarian’s request) to BioStone’s USDA-licensed facility in Grand Prairie, Texas. We manufacture autogenous bacterins/bacterin-toxoids with up to five isolates, in the dose quantity requested, typically shipping within 6-8 weeks to the prescribing veterinarian for use.
Manufactured in the United States
Autogenous bacterins must be produced at a USDA-licensed establishment authorized for vaccine production. BioStone owns and operates a 16,300-square-foot USDA-licensed facility (Est. 315) in Grand Prairie, Texas, acquired from American Animal Health (AAH) along with key personnel and manufacturing systems. Through this acquisition, BioStone continues a legacy of autogenous bacterin manufacturing dating back to 1983.
